NAC does not dissolve preexisting VWF-rich thrombi in vitro. (A) NHP was incubated with 0 or 32 mM NAC, and plasma was subsequently added to lyophilized platelets (n = 3 per condition). Platelet agglutination was started by addition of ristocetin. Anti-GP1b antibody 6B4 was added at 20 nM to block the VWF-platelet interaction. The percentage of aggregation reached at 12 minutes was used for quantification. (B) Representative traces from 3 different experiments are shown. (C) Platelet agglutination was induced by addition of ristocetin to a mixture of NHP and lyophilized platelets. NAC (0 or 32 mM) was added when the agglutinate was stably formed (indicated with an arrow). The percentage of aggregation reached at 30 minutes was used for quantification. (D) Representative traces from 3 different experiments are shown. Graphs represent the mean ± standard deviation. Statistical significance is indicated with asterisks: ***P < .001.